IgE, IgG and patient‐self tests during slow hyposensitization to grass pollen

Blair, Henry; Ezeoke, A. C. J.; Hobbs, J.R.

doi:10.1111/j.1365-2222.1975.tb01861.x

Cited by 4 publications

(1 citation statement)

References 10 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 166 An increase in the blocking IgG antibodies can be assessed by a traditional functional test with patient serum (referred to as a “patient self-test” or “P-S test”) and other means. 166 – 169 This is critical, as these latter antibodies compete with FcRεI-immobilized IgE antibodies for allergen binding. Specifically, stabilization of the cells capable of degranulation by reducing the chance of IgE cross-linking and increasing activation threshold reduces risk of type I hypersensitivity reactions and IgE-mediated antigen presentation by the APCs.…”

Section: Mechanisms Underlying Aitmentioning

confidence: 99%

Therapeutic vaccines for allergic disease

Gutowska-Owsiak

Ogg

2017

npj Vaccines

View full text Add to dashboard Cite

Allergic diseases are highly prevalent worldwide and affect all age groups, contributing to a high personal and socioeconomic burden. Treatment with an “allergy vaccine” or allergen immunotherapy aims to provide long-lasting benefits by inducing unresponsiveness to the relevant antigen. The consequences of the therapy are considered disease modifying and range from dampening of the immediate immune responses to the reduction of secondary tissue remodeling. Furthermore, allergen immunotherapy interventions have a potential to slow or cease the development of additional allergic manifestations with a long-term overall effect on morbidity and quality of life. Here, we review proposed mechanisms underlying the therapeutic effects of immunotherapy for allergic diseases. Further, we discuss both standard and novel approaches and possible future directions in the development of allergen immunotherapy.

show abstract

Section: Mechanisms Underlying Aitmentioning

confidence: 99%

Therapeutic vaccines for allergic disease

Gutowska-Owsiak

Ogg

2017

npj Vaccines

View full text Add to dashboard Cite

show abstract

Determination of Specific IgE and IgG Serum Antibodies During Immunotherapy in Hay Fever Patients by RAST

Osterhage

Wippler

Kalden

et al. 1977

Zeitschrift für Immunitätsforschung: Immunobiology

View full text Add to dashboard Cite

A comparative trial of hyposensitization in 1973 in the treatment of hay fever using Pollinex and Alavac‐P

Miller

1976

Clin Experimental Allergy

View full text Add to dashboard Cite

Summary A direct comparison was made in 112 hay fever patients of hyposensitization treatment with glutaraldehyde‐pollen‐tyrosine adsorbate (Pollinex) and with alum‐precipitated pyridine extract (Alavac‐P) which is an accepted form of treatment, its efficacy having been shown by a comparative trial against a placebo preparation. No significant difference could be detected between the results of the two forms of treatment. Seventy‐seven per cent of patients responded with improvement following treatment with the tyrosine adsorbed vaccine, and 81% of those receiving the alum‐precipitated vaccine. Side effects from treatment, both local and general, were generally of an infrequent or mild nature for both vaccines.

show abstract

IgE, IgG and patient‐self tests during slow hyposensitization to grass pollen

Cited by 4 publications

References 10 publications

Therapeutic vaccines for allergic disease

Therapeutic vaccines for allergic disease

Determination of Specific IgE and IgG Serum Antibodies During Immunotherapy in Hay Fever Patients by RAST

A comparative trial of hyposensitization in 1973 in the treatment of hay fever using Pollinex and Alavac‐P

Contact Info

Product

Resources

About